Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium

Gustavo H Vázquez, Anees Bahji, Juan Undurraga, Leonardo Tondo, Ross J Baldessarini, Gustavo H Vázquez, Anees Bahji, Juan Undurraga, Leonardo Tondo, Ross J Baldessarini

Abstract

Background: Successful treatment of major depressive disorder (MDD) can be challenging, and failures ("treatment-resistant depression" [TRD]) are frequent. Steps to address TRD include increasing antidepressant dose, combining antidepressants, adding adjunctive agents, or using nonpharmacological treatments. Their relative efficacy and tolerability remain inadequately tested. In particular, the value and safety of increasingly employed second-generation antipsychotics (SGAs) and new esketamine, compared to lithium as antidepressant adjuncts remain unclear.

Methods: We reviewed randomized, placebo-controlled trials and used random-effects meta-analysis to compare odds ratio (OR) versus placebo, as well as numbers-needed-to-treat (NNT) and to-harm (NNH), for adding SGAs, esketamine, or lithium to antidepressants for major depressive episodes.

Results: Analyses involved 49 drug-placebo pairs. By NNT, SGAs were more effective than placebo (NNT = 11 [CI: 9-15]); esketamine (7 [5-10]) and lithium (5 [4-10]) were even more effective. Individually, aripiprazole, olanzapine+fluoxetine, risperidone, and ziprasidone all were more effective (all NNT < 10) than quetiapine (NNT = 13), brexpiprazole (16), or cariprazine (16), with overlapping NNT CIs. Risk of adverse effects, as NNH for most-frequently reported effects, among SGAs versus placebo was 5 [4-6] overall, and highest with quetiapine (NNH = 3), lowest with brexpiprazole (19), 5 (4-6) for esketamine, and 9 (5-106) with lithium. The risk/benefit ratio (NNH/NNT) was 1.80 (1.25-10.60) for lithium and much less favorable for esketamine (0.71 [0.60-0.80]) or SGAs (0.45 [0.17-0.77]).

Conclusions: Several modern antipsychotics and esketamine appeared to be useful adjuncts to antidepressants for acute major depressive episodes, but lithium was somewhat more effective and better tolerated.

Limitations: Most trials of adding lithium involved older, mainly tricyclic, antidepressants, and the dosing of adjunctive treatments were not optimized.

Keywords: Antidepressants; antipsychotics; combination; depression; efficacy; esketamine; lithium.

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Forest plots of random-effects meta-analyses for clinical trials testing the efficacy of supplementing antidepressants with active agents or placebo for major depression: (a) second-generation antipsychotics (SGAs, 28 trials), (b) intranasal esketamine (7 trials), or (c) lithium carbonate (13 trials). SGAs tested were: APZ, aripiprazole; BRX, brexpiprazole; CAR, cariprazine; OFC, olanzapine+fluoxetine combination; QTP, quetiapine; RSP, risperidone; ZPS, ziprasidone. Adding all three types of active treatments were much more effective than adding placebo: (a) SGAs: pooled OR = 1.59 [CI: 1.44–1.75]; z-score = 9.16, p < 0.0001; (b) esketamine: pooled OR = 1.85 [1.45–2.35]; z-score = 4.98, p < 0.0001; Lithium: pooled OR = 2.12 [1.46–3.09]; z = 3.92, p < 0.0001. Heterogeneity ratings (I2) all were <1.0%.
Figure A1.
Figure A1.
Flow-chart of selection of reports for inclusion in study, based on PRISMA recommendations (http://www.prisma-statement.org/PRISMAStatement/PRISMAStatement) to yield 39 reports (with 43 trials) included for analysis.

References

    1. Andrade C. (2015) The numbers needed to treat and harm (NNT, NNH) statistics: What they tell us and what they do not. J Clin Psychiatry 76: e330–e333. DOI: 10.4088/JCP.15f09870.
    1. Bahji A, Ermacora D, Stephenson C, et al.. (2020) Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: Systematic review and network meta-analysis. J Affect Disord 269: 154–184. DOI: 10.1016/j.jad.2020.03.030.
    1. Bahji A, Vázquez GH, Zarate CA. (2021) Comparative efficacy of racemic ketamine and esketamine for depression: Systematic review and meta-analysis. J Affect Disord 271: 542–555. DOI: 10.1016/j.jad.2020.09.071.
    1. Baldessarini RJ. (2013) Chemotherapy in Psychiatry: Pharmacologic Basis of Treatments for Major Mental Illness, 3rd edn. New York, NY: Springer-Verlag.
    1. Baldessarini RJ, Tondo L. (2020) Suicidal risks in 12 DSM-5 psychiatric disorders. J Affect Disord 271: 66–73. DOI: 10.1016/j.jad.2020.03.083.
    1. Bauer M, Pretorius HW, Constant EL, et al.. (2009) Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double blind study. J Clin Psychiatry 70: 540–549.
    1. Bauer M, Pfennig A, Severus E, et al.. (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 14: 334–385. DOI: 10.3109/15622975.2013.804195.
    1. Baumann P, Nil R, Souche A, et al.. (1996) Double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: Clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 16: 307–314.
    1. Berman RM, Marcus RN, Swanink R, et al.. (2007) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68: 843–853.
    1. Berman RM, Fava M, Thase ME, et al.. (2009) Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 14: 197–206.
    1. Bloch M, Schwartzman Y, Bonne O, et al.. (1997) Concurrent treatment of nonresistant major depression with desipramine and lithium: Double-blind, placebo-controlled study. J Clin Psychopharmacol 17: 44–48. DOI: 10.1097/00004714-199702000-00008.
    1. Browne M, Lapierre YD, Hrdina PD, et al.. (1990) Lithium as an adjunct in the treatment of major depression. Int Clin Psychopharmacol 5: 103–110. DOI: 10.1097/00004850-199004000-00004.
    1. Canuso CM, Singh JB, Fedgchin M, et al.. (2018) Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 175: 620–630. DOI: 10.1176/appi.ajp.2018.17060720.
    1. Cappiello A, McDougle CJ, Delgado PL, et al.. (1998) Lithium and desipramine vs. desipramine alone in the treatment of severe major depression: a preliminary study. Int Clin Psychopharmacol 13: 191–198. DOI: 10.1097/00004850-199809000-00001.
    1. Celano CM, Villegas AC, Albanese AM, et al.. (2018) Depression and anxiety in heart failure: Review. Harv Rev Psychiatry 26: 175–184. DOI: 10.1097/HRP.0000000000000162.
    1. Centorrino F, Masters GA, Talamo A, et al.. (2012) Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Hum Psychopharmacol 27: 521–526. DOI: 10.1002/hup.2257.
    1. Citrome L, Ketter TA. (2013) When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract 67: 407–411. DOI: 10.1111/ijcp.12142.
    1. Corya SA, Williamson D, Sanger TM, et al.. (2006) A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 23: 364–372.
    1. Daly EJ, Singh JB, Fedgchin M, et al.. (2018) Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: Randomized clinical trial. JAMA Psychiatry 75: 139–148. DOI: 10.1001/jamapsychiatry.2017.3739.
    1. Davies P, Ijaz S, Williams CJ, et al.. (2019) Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev 12: CD010557. DOI: 10.1002/14651858.CD010557.pub2.
    1. Durgam S, Earley W, Guo H, et al.. (2016) Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry 77: 371–378.
    1. Earley WR, Guo H, Nemeth G, et al.. (2018) Cariprazine augmentation to antidepressant therapy in major depressive disorder: Results of a randomized, double-blind, placebo-controlled trial. Psychopharmacol Bull 48: 62–80.
    1. El-Khalili N, Joyce M, Atkinson S, et al.. (2010) Extended release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multicentre, randomized, double-blind, placebo controlled study. Int J Neuropsychopharmacol 13: 917–932.
    1. Fava M, Mischoulon D, Iosifescu D, et al.. (2012) A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 81(2): 87–97.
    1. Fava M, Durgam S, Earley W, et al.. (2018) Efficacy of adjunctive low-dose cariprazine in major depressive disorder: A randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 33: 312–321.
    1. Fedgchin M, Trivedi M, Daly EJ, et al.. (2019) Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol 22: 616–630. DOI: 10.1093/ijnp/pyz039.
    1. Ferrari AJ, Somerville AJ, Baxter AJ, et al.. (2013) Global variation in the prevalence and incidence of major depressive disorder: Systematic review of the epidemiological literature. Psychol Med 43: 471–481. DOI: 10.1017/S0033291712001511.
    1. Forte A, Baldessarini RJ, Tondo L, et al.. (2015) Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders. J Affect Disord 178: 71–78. DOI: 10.1016/j.jad.2015.02.011.
    1. Fu D-J, Ionescu DF, Li X, et al.. (2020) Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: Double-blind, randomized study (ASPIRE I). J Clin Psychiatry 81: 19m13191. DOI: 10.4088/JCP.19m13191.
    1. Gierisch JM, Nieuwsma JA, Bradford DW, et al.. (2014) Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: A systematic review and meta-analysis. J Clin Psychiatry 75: e424–440. DOI: 10.4088/JCP.13r08558.
    1. Haddad PM, Talbot PS, Anderson IM, et al.. (2015) Managing inadequate antidepressant response in depressive illness. Br Med Bull 115: 183–201. DOI: 10.1093/bmb/ldv034.
    1. Hamilton M. (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62.
    1. Heninger GR, Charney DS, Sternberg DE. (1983) Lithium carbonate augmentation of antidepressant treatment: An effective prescription for treatment-refractory depression. Arch Gen Psychiatry 40: 1335–1342. DOI: 10.1001/archpsyc.1983.01790110077013.
    1. Higgins JPT, Thompson SG. (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558. DOI: 10.1002/sim.1186.
    1. Hobart M, Skuban A, Zhang P, et al.. (2018. a) A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder. J Clin Psychiatry 79(4): 17m12058.
    1. Hobart M, Skuban A, Zhang P, et al.. (2018. b) Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: A randomized, active-referenced, placebo-controlled study. Curr Med Res Opin 34(4): 633–642.
    1. Ionescu DF, Fu D-J, Qiu X, et al.. (2021) Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a Phase 3, double-blind, randomized study (ASPIRE II). Int J Neuropsychopharmacol 24: 22–31. DOI: 10.1093/ijnp/pyaa068.
    1. Januel D, Poirier M-F, D’alche-Biree F, et al.. (2003) Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression. J Affect Disord 76: 191–200. DOI: 10.1016/s0165-0327(02)00086-1.
    1. Joffe RT, Levitt AJ, Bagby RM, et al.. (1993) Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders. Br J Psychiatry 163: 574–578. DOI: 10.1192/bjp.163.5.574.
    1. Katona CL, Abou-Saleh MT, Harrison DA, et al.. (1995) Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 166: 80–86. DOI: 10.1192/bjp.166.1.80.
    1. Katsanos K, Spiliopoulos S, Saha P, et al.. (2015) Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: Systematic review and network meta-analysis. PLoS One 10: e0135692. DOI: 10.1371/journal.pone.0135692.
    1. Keitner GI, Garlow SJ, Ryan CE, et al.. (2009) A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 43: 205–214.
    1. Kennedy SH, Lam RW, McIntyre RS, et al.. (2016) Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder. Can J Psychiatry 61: 540–560. DOI: 10.1177/0706743716659417.
    1. Liberati A, Altman DG, Tetzlaff J, et al.. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation andelaboration. PLoS Med 6: e1000100. DOI: 10.1371/journal.pmed.1000100.
    1. Lingjærde O, Edlund AH, Gormsen CA, et al.. (1974) Effect of lithium carbonate in combination with tricyclic antidepressants in endogenous depression: Double-blind, multicenter trial. Acta Psychiatr Scand 50: 233–242. DOI: 10.1111/j.1600-0447.1974.tb08212.x.
    1. MacQueen G, Santaguida P, Keshavarz H, et al.. (2017) Systematic review of clinical practice guidelines for failed antidepressant treatment response in major depressive disorder, dysthymia, and subthreshold depression in adults. Can J Psychiatry 62: 11–23. DOI: 10.1177/0706743716664885.
    1. Mahmoud RA, Pandina GJ, Turkoz I, et al.. (2007) Risperidone for treatment-refractory major depressive disorder: A randomized trial. Ann Intern Med 147: 593–602.
    1. Marcus RN, McQuade RD, Carson WH, et al.. (2008) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28: 156–165.
    1. McIntyre A, Gendron A, McIntyre A. (2007) Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: A randomized, placebo controlled pilot study. Depress Anxiety 24: 487–494.
    1. Mendes D, Alves C, Batel-Marques F. (2017) Number needed to treat (NNT) in clinical literature: An appraisal. BMC Med 15: 112. DOI: 10.1186/s12916-017-0875-8.
    1. Milev RV, Giacobbe P, Kennedy SH, et al.. (2016) Canadian network for mood and anxiety treatments (CANMAT) clinical guidelines for the management of adults with major depressive disorder: Section 4. Neurostimulation treatments. Can J Psychiatry 61: 561–575. DOI: 10.1177/0706743716660033.
    1. Montgomery SA, Åsberg M. (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382–389.
    1. Mulder R, Hamilton A, Irwin L, et al.. (2018) Treating depression with adjunctive antipsychotics. Bipolar Disord 20: 17–24. DOI: 10.1111/bdi.12701.
    1. Nelson JC, Papakostas GI. (2009) Atypical antipsychotic augmentation in major depressive disorder: Meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166: 980–991. DOI: 10.1176/appi.ajp.2009.09030312.
    1. Nierenberg AA, Papakostas GI, Petersen T, et al.. (2003) Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol 23: 92–95.
    1. Ochs-Ross R, Daly EJ, Zhang Y, et al.. (2020) Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression—TRANSFORM-3. Am J Geriatr Psychiatry 28: 121–141. DOI: 10.1016/j.jagp.2019.10.008.
    1. Parikh SV, Segal ZV, Grigoriadis S, et al.. (2009) Canadian network for mood and anxiety treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord 117: S15–S25. DOI: 10.1016/j.jad.2009.06.042.
    1. Papakostas GI, Fava M, Baer L, et al.. (2015) Ziprasidone augmentation of escitalopram for major depressive disorder: Efficacy results from a randomized, double-blind, placebo-controlled study. Am J Psychiatry 172(12): 1251–1258.
    1. Popova V, Daly EJ, Trivedi M, et al.. (2019) Efficacy and safety of flexibly dosed esketamine nasal spray combined with newly initiated oral antidepressant in treatment-resistant depression: Randomized double-blind active-controlled study. Am J Psychiatry 176: 428–438. DOI: 10.1176/appi.ajp.2019.19020172.
    1. Reeves H, Batra S, May RS, et al.. (2008) Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: A randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 69: 1228–1336.
    1. Ruberto VL, Jha MK, Murrough JW. (2020) Pharmacological treatments for patients with treatment-resistant depression. Pharmaceuticals 13: 116–138. DOI: 10.3390/ph13060116.
    1. Rush AJ, Kraemer HC, Sackeim HA, et al.. (2006) Report by ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 31: 1841–1853. DOI: 10.1038/sj.npp.1301131.
    1. Saini R, Raju MSVK, Chaudhury S, et al.. (2016) Accelerated antidepressant response to lithium augmentation of imipramine. Ind Psychiatry J 25: 93–100. DOI: 10.4103/0972-6748.196057.
    1. Schöpf J, Baumann P, Lemarchand T, et al.. (1989) Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition: Results of a placebo-controlled double-blind study. Pharmacopsychiatry 22: 183–187. DOI: 10.1055/s-2007-1014603.
    1. Seligman F, Nemeroff CB. (2015) The interface of depression and cardiovascular disease: Therapeutic implications. Ann N Y Acad Sci 1345: 25–35. DOI: 10.1111/nyas.12738.
    1. Shelton RC, Tollefson GD, Tohen M, et al.. (2001) A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158: 131–134.
    1. Shelton RC, Williamson DJ, Corya SA, et al.. (2005) Olanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 66: 1289–1297.
    1. Solmi M, Murru A, Pacchiarotti I, et al.. (2017) Safety, tolerability, and risks associated with first- and second-generation antipsychotics: A state-of-the-art clinical review. Ther Clin Risk Manag 13: 757–777. DOI: 10.2147/TCRM.S117321.
    1. Spielmans GI, Berman MI, Linardatos E, et al.. (2013) Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 10: e1001403. DOI: 10.1371/journal.pmed.1001403.
    1. Stein G, Bernadt M. (1993) Lithium augmentation therapy in tricyclic-resistant depression: Controlled trial using lithium in low and normal doses. Br J Psychiatry 162: 634–640. DOI: 10.1192/bjp.162.5.634.
    1. Thase ME, Corya SA, Osuntokun O, et al.. (2007) A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 68: 224–236.
    1. Thase ME, Youakim JM, Skuban A, et al.. (2015. a) Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: A phase 3, randomized, double-blind study. J Clin Psychiatry 76(9): 1232–1240.
    1. Thase ME, Youakim JM, Skuban A, et al.. (2015. b) Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: A phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 76(9): 1224–1231.
    1. Tondo L, Vázquez GH, Pinna M, et al.. (2018) Characteristics of depressive and bipolar disorder patients with mixed features. Acta Psychiatr Scand 138: 243–252. DOI: 10.1111/acps.12911.
    1. Undurraga J, Sim K, Tondo L, et al.. (2019) Lithium treatment for unipolar major depressive disorder: Systematic review. J Psychopharmacol 33: 167–176. DOI: 10.1177/0269881118822161.
    1. Vázquez GH, Lolich M, Cabrera C, et al.. (2018) Mixed symptoms in major depressive and bipolar disorders: Systematic review. J Affect Disord 225: 756–760. DOI: 10.1016/j.jad.2017.09.006.
    1. World Health Organization (2012) Global burden of disease: Depression. Available at: (accessed 28 December 2020).
    1. Yuan Z, Chen Z, Xue M, et al.. (2020) Application of antidepressants in depression: Systematic review and meta-analysis. J Clin Neurosci 80: 169–181. DOI: 10.1016/j.jocn.2020.08.013.
    1. Zimmermann P, Brückl T, Nocon A, et al.. (2009) Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity. Arch Gen Psychiatry 66: 1341–1352. DOI: 10.1001/archgenpsychiatry.2009.158.
    1. Zusky PM, Biederman J, Rosenbaum JF, et al.. (1988) Adjunct low dose lithium carbonate in treatment-resistant depression: Placebo-controlled study. J Clin Psychopharmacol 8: 120–124. DOI: 10.1097/00004714-198804000-00007.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner